Welcome to your personal Web site for PATANASE® Nasal Spray,
the only allergy spray with 30-minute onset approved by the FDA.1-4
Explore our new interactive sessions! All of our sessions should take just 2 to 3 minutes to complete.


Learn more about use in the general population in the sessions below:
  
Learn more about use in pediatric populations in the sessions below:
How do your perceptions of allergy treatments compare to those of your patients? Find out in our Perceptual Maps.
START NOW

Test your allergy IQ in our
Word Catch Challenge!

START NOW
You're the expert, so tell us what you want to see! Provide your clinical expertise to our marketing team to construct a virtual sales aid.
START NOW 3
 

Join us for a game of concentration and learn more about what parents and pediatric allergy patients think about current nasal allergy treatments.

START NOW 4
 

 

INDICATIONS AND USAGE
PATANASE® Nasal Spray is an H1 receptor antagonist indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and children 6 years of age and older.

Dosing and Administration: Recommended dosages:

bullet
Adults and adolescents ≥12 years: Two sprays per nostril twice daily.
bullet
Children 6 to 11 years: One spray per nostril twice daily.

IMPORTANT SAFETY INFORMATION
Warnings and Precautions:

bullet
Epistaxis, nasal ulceration, and nasal septal perforation. Monitor patients periodically for signs of adverse effects on the nasal mucosa. Discontinue if ulcerations or perforations occur. Avoid use in patients with nasal disease other than allergic rhinitis.
 
bullet
Avoid engaging in hazardous occupations requiring complete mental alertness such as driving or operating machinery when taking PATANASE® Nasal Spray.
 
bullet
Avoid concurrent use of alcohol or other central nervous system depressants with PATANASE® Nasal Spray.
 
Adverse Events:
The most common adverse reactions (>1%) included bitter taste, headache, epistaxis, pharyngolaryngeal pain, post-nasal drip, cough, and urinary tract infection in patients 12 years of age and older and epistaxis, headache, upper respiratory tract infection, bitter taste, pyrexia, and rash in patients 6 to 11 years of age.

Click here for full prescribing information.

alconlogo alconlogo

References:
1. PATANASE® Nasal Spray package insert. 2. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc. 2007;28:592-599. 3. Patel P, Roland P, Marple B, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg. 2007;137:918-924. 4. Patel P, Patel D, Edwards M, et al. Onset of action of olopatadine hydrochloride nasal spray 0.6% (Patanase®) in the treatment of allergic rhinitis. Poster presented at: American Academy of Allergy, Asthma, and Immunology (AAAAI); March 14-18, 2008; Philadelphia, PA.

©2010 Alcon, Inc. 08/10 PTN10505WB-E